Long-Term Impact of Cyclosporin Reduction with MMF Treatment in Chronic Allograft Dysfunction: REFERENECE Study 3-Year Follow Up

Table 2

(a) MMF treatment.

	Randomization population${}^1$				On-treatment population^2
	MMF group${}^3$		Control group${}^4$		Group I${}^5$		Group II${}^6$
	Patients under; MMF 2g/day	Mean MMF; dose/day	Patients under; MMF treatment	Mean MMF; dose/day	Patients under; MMF 2 g/day	Mean MMF dose/day	Patients under; MMF treatment	Mean MMF; dose/day
M30	36 (75.0%)	1844$\hspace{0.17em}\pm \hspace{0.17em}$295 mg	2 (9.0%)	125  $\pm \hspace{0.17em}$ 448 mg	36 (64.3%)	1549  $\pm$  741 mg	3 (21.4%)	321 $\pm$ 668 mg
M48	31 (70.5%)	1773$\hspace{0.17em}\pm \hspace{0.17em}$424 mg	6 (33.4%)	500 $\pm$ 786 mg	33 (66.0%)	1650 $\pm$ 600 mg	3 (25.0%)	375 $\pm$ 711 mg
M60	26 (60.5%)	1628 $\pm$ 608 mg	9 (47.4%)	711 $\pm$ 822 mg	29 (59.2%)	1704 $\pm$ 432 mg	0	—

${}^1$ Patients randomized to receive either MMF or CsA treatment in the initial study phase.
${}^2$ Determined by the treatment patients received at the end of the post-trial phase (mycophenolic acid derivative or not).
${}^3$ Patients who received 2 g MMF per day and 50% of the initial CsA dose.
${}^4$ Patients who received the usual CsA dose
${}^5$ Patients who received a treatment with a mycophenolic acid derivative at the end of the follow up phase.
${}^6$ Patients without a mycophenolic acid derivative at the end of the follow up phase.

(b) Mean CsA dose per day.

	Randomization population${}^1$		On-treatment population${}^2$
	MMF group${}^3$	Control group${}^4$	Group I${}^5$	Group II${}^6$
M30	129 $\pm$ 37 mg	190 $\pm$ 50 mg	137 $\pm$ 48 mg	191 $\pm$ 30 mg
M48	134 $\pm$ 47 mg	180 $\pm$ 54 mg	134 $\pm$ 41 mg	205 $\pm$ 60 mg
M60	126 $\pm$ 44 mg	163 $\pm$ 43 mg	128 $\pm$ 37 mg	173 $\pm$ 63 mg

${}^1$ Patients randomized to receive either MMF or CsA treatment in the initial study phase.
${}^2$ Determined by the treatment patients received at the end of the post-trial phase (mycophenolic acid derivative or not).
${}^3$ Patients who received 2 g MMF per day and 50% of the initial CsA dose.
${}^4$ Patients who received the usual CsA dose.
${}^5$ Patients who received a treatment with a mycophenolic acid derivative at the end of the follow up phase.
${}^6$ Patients without a mycophenolic acid derivative at the end of the follow up phase.